
turkin markingo



F16.1





FIG. 2



F16.3




FIG. 4





FIG. 5




F16. 6

A A endogenous glypican-1
glyp1-VSVGTMR

C-myc epitope

F1G. 7



F16.8






FIG. 9




FIG. 10




FIG. 11






FIG. 12











FIG. 13

PCT/US99/24176







FIG. 14






FIG. 15







FIG. 16



ratio of glypican or syndecan-1 and 7S RNA





A. mRNA 7S (-) (+) (-) (+) heparitinase B. total lysate C. membrane D. secreted component

FIG. 20




FIG. 21

MDA-MB-231 MDA-MB-468

nRNA


22/26


7S

B. total lysate

C. secreted component

FIG. 22








FIG. 23







FIG. 24


MDA-MB-231














FIG. 25


Cell Growth (% of control)


PCT/US99/24176


26/26


MDA-MB-468

















FIG. 26